Trial Profile
A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery (SAVE HIP 2) [Estudio Multinacional, Multicéntrico, Randomizado, Doble Ciego, para comparar la eficacia y seguridad de AVE5026 frente a enoxaparina en la Prevención de Tromboembolismo Venoso en Pacientes sometidos a Cirugía de Fractura de Cadera]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Semuloparin (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Venous thromboembolism
- Focus Registrational; Therapeutic Use
- Acronyms SAVE-HIP2
- Sponsors Sanofi
- 16 Mar 2012 Primary endpoint 'Venous-thromboembolism-event-rate' has not been met according to results published in the Journal of Thrombosis and Haemostasis.
- 03 Feb 2010 Sanofi Synthelabo added as trial sponsor and lead centre as reported by Clinical Trials Registry - India record.
- 03 Feb 2010 New source identified and integrated (Clinical Trials Registry - India record).